Kaur Indu P, Garg Alka, Singla Anil K, Aggarwal Deepika
University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160 014, India.
Int J Pharm. 2004 Jan 9;269(1):1-14. doi: 10.1016/j.ijpharm.2003.09.016.
The main aim of pharmacotherapeutics is the attainment of effective drug concentration at the intended site of action for a sufficient period of time to elicit a response. Poor bioavailability of drugs from ocular dosage form is mainly due to the tear production, non-productive absorption, transient residence time, and impermeability of corneal epithelium. Though the topical and localized application are still an acceptable and preferred way to achieve therapeutic level of drugs used to treat ocular disorders but the primitive ophthalmic solution, suspension, and ointment dosage form are no longer sufficient to combat various ocular diseases. This article reviews the constraints with conventional ocular therapy and explores various novel approaches, in general, to improve ocular bioavailability of the drugs, advantages of vesicular approach over these and the future challenges to render the vesicular system more effective.
药物治疗学的主要目标是在预期作用部位达到有效的药物浓度,并持续足够长的时间以引发反应。眼用剂型药物的生物利用度差主要是由于泪液分泌、无效吸收、短暂停留时间以及角膜上皮的不渗透性。尽管局部和定位给药仍然是达到用于治疗眼部疾病药物治疗水平的可接受且首选的方式,但传统的眼药水、混悬剂和眼膏剂型已不足以对抗各种眼部疾病。本文综述了传统眼部治疗的局限性,探讨了一般用于提高药物眼部生物利用度的各种新方法、囊泡方法相对于这些方法的优势以及使囊泡系统更有效的未来挑战。